Experienced in Chronic Inflammatory Demyelinating Polyneuropathy

Byoung J. Kim

Seoul, KR 
Experienced in Chronic Inflammatory Demyelinating Polyneuropathy
Seoul, KR 
OverviewLocationsClinical Research

Overview

Byoung Kim practices in Seoul, Republic of Korea. Kim is rated as an Experienced expert by MediFind in the treatment of Chronic Inflammatory Demyelinating Polyneuropathy. Their top areas of expertise are Transverse Myelitis, Neuromyelitis Optica, Optic Neuritis, Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease, and Thymectomy.

Their clinical research consists of co-authoring 99 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 3 articles in the study of Chronic Inflammatory Demyelinating Polyneuropathy.

Locations

Seoul, Republic of Korea
Other Locations
Yangsan, Republic of Korea
Republic of Korea

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Double-blind, Randomized, Multicenter, Placebo-Controlled, Parallel, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Lenzumestrocel(Neuronata-R® Inj.) in Patients with Amyotrophic Lateral Sclerosis
A Double-blind, Randomized, Multicenter, Placebo-Controlled, Parallel, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Lenzumestrocel(Neuronata-R® Inj.) in Patients with Amyotrophic Lateral Sclerosis
Enrollment Status: Active_not_recruiting
Publish Date: January 10, 2025
Intervention Type: Drug, Biological
Study Drugs: Lenzumestrocel, Riluzole
Study Phase: Phase 3
A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib Compared With an Interferon Beta 1a (Avonex®), in Participants With Relapsing Multiple Sclerosis to Evaluate Efficacy and Safety
A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib Compared With an Interferon Beta 1a (Avonex®), in Participants With Relapsing Multiple Sclerosis to Evaluate Efficacy and Safety
Enrollment Status: Terminated
Publish Date: August 05, 2021
Intervention Type: Drug
Study Phase: Phase 3
View 1 Less Clinical Trial

99 Total Publications

Genetic susceptibility of human leukocyte antigen alleles in chronic inflammatory demyelinating polyneuropathy in Korean patients : Short title: HLA alleles and CIDP in Korea.
Genetic susceptibility of human leukocyte antigen alleles in chronic inflammatory demyelinating polyneuropathy in Korean patients : Short title: HLA alleles and CIDP in Korea.
Journal: BMC neurology
Published: April 21, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Kim's expertise for a condition
ConditionClose
    View All 31 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile